35th week of 2009 patent applcation highlights part 48 |
Patent application number | Title | Published |
20090215699 | Pharmaceutically Active Antiviral Peptides - The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects. | 2009-08-27 |
20090215700 | Metastin derivatives and use thereof - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). | 2009-08-27 |
20090215701 | Enhancement of Iron Chelation Therapy - The present invention provides methods of enhancing the rate of iron release from ferritin. By increasing the amount of iron available for chelation, the invention also provides methods of treating conditions associated with iron overload. The invention also provides in one embodiment agents which are useful for treating iron overload. | 2009-08-27 |
20090215702 | Uv-Induced Dermatitis Inhibitor and Atopic Dermatitis Inhibitor - At least one substance selected from the group consisting of a water-soluble peptide comprising at least one unit selected from the group consisting of an isoleucylglycylseryl unit, a prolylisoleucylglycylseryl unit, a glycylprolylisoleucylseryl unit, a glycylprolylisoleucylglycylthreonyl unit, a prolylisoleucylglycyl unit and a glycylprolylisoleucylglycyl unit and a water-soluble salt thereof can be used as an UV-induced dermatitis inhibitor or atopic dermatitis inhibitor. | 2009-08-27 |
20090215703 | PAR-2 Agonist - The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition. The pharmaceutical composition comprises a compound represented by the following general formula (1), salt or solvate thereof and a pharmaceutically acceptable carrier: Ar—CO-AA | 2009-08-27 |
20090215704 | HEALTH-RELATED LIQUID COMPOSITIONS - There are disclosed liquid compositions comprising water, a fiber such as inulin, and a glycosaminoglycan that is selected from chondroitin sulfate, glucosamine, or a mixture thereof. The liquid compositions may further comprise at least one or more sweeteners, a source of calcium, at least one or more flavor additives, trehalose, at least one or more acids, sodium citrate, monopotassium phosphate, fruit juice, fruit juice concentrate, or the like, and any combination thereof. The liquid compositions may be suitable for use in health-related applications, among other applications. | 2009-08-27 |
20090215705 | Alpha 7 Nicotinic Receptor Selective Ligands - The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration. | 2009-08-27 |
20090215706 | C-LINKED GLUCURONIDE OF N-(4-HYDROXYBENZYL) RETINONE, ANALOGS THEREOF, AND METHOD OF USING THE SAME TO INHIBIT NEOPLASTIC CELL GROWTH - Compounds of the formula: | 2009-08-27 |
20090215707 | COMPOUND HAVING CYCLIC STRUCTURE AND USE THEREOF - The present invention relates to a compound represented by the following formula (1′) | 2009-08-27 |
20090215709 | Methylation markers for diagnosis and treatment of cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments. | 2009-08-27 |
20090215710 | CARBOHYDRATE BASED TOLL-LIKE RECEPTOR (TLR) ANTAGONISTS - The invention provides carbohydrate based compounds, methods of preparation, and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a carbohydrate based compound of the invention having a core structure comprising of one or more sugar moieties. The carbohydrate based compounds are useful for inhibiting immune stimulation involving TLR ligands, especially TLR4 and TLR2. The compounds also are suitable for inhibition of inflammatory conditions resulting from infections. The compounds have use in the treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency. | 2009-08-27 |
20090215711 | Novel compositions and methods in cancer - The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer. | 2009-08-27 |
20090215712 | PYRAZOLE DERIVATIVES - This invention relates to pyrazole derivatives of formula (I) | 2009-08-27 |
20090215713 | Use of atp for the manufacture of a medicament for the prevention and treatment of oxidative stress and related conditions - The present invention provides the use of ATP for the manufacture of a medicine comprising ATP as an active ingredient for exerting a preventive or therapeutic pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: a. modulating oxidative stress and the effects thereof by favourably affecting the formation or scavenging of aggressive hydroxyl radicals; b. modulating the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin, even under conditions of severe oxidative stress; c. inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS) and/or phytohaemagglutinin under conditions of severe oxidative stress; d. exerting a local protective effect against oxidative stress in the intestine, thus preventing intestinal damage induced by several types of medication such as non steroid anti-inflammatory drugs (NSAIDs); e. exerting favourable immuno-modulating and oxidative stress-reducing effects in blood from patients with oxidative stress-related disorders; and f. exerting favourable clinical effects in patients with different oxidative stress-related disorders such as, but not limited to, rheumatoid arthritis, intestinal disease, cancer and fatigue. The medicine is preferably manufactured in lyophilized form. | 2009-08-27 |
20090215714 | Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder - The invention is based on the discovery that specific dosages of pyrimidine compositions, such as cytidine compositions, can be used to treat patients diagnosed with bipolar disorder. | 2009-08-27 |
20090215715 | Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer - Phosphoramidate derivatives of nucleoside compounds such as cladribine, isocladribine, fludaribine and clofarabine have enhanced therapeutic potency in | 2009-08-27 |
20090215716 | NITROGUANOSINE-3' 5'-CYCLIC MONOPHOSPHATE COMPOUND AND PROTEIN KINASE G ACTIVATING AGENT - An object of the present invention is to provide a novel compound that is an agonist of guanosine-3′,5′-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3′,5′-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3′,5′-cyclic monophosphate compound as an active ingredient. | 2009-08-27 |
20090215717 | Sulfated oligosaccharides - The invention relates to sulfated oligosaccharides, more particularly to new pharmaceutical uses of sulfated oligosaccharides. The invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic’, inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. The invention further provides use of a sulfated oligosaccharide in the preparation of a medicament for the treatment of acute and chronic inflammatory disorders of the airways of mammals. The invention yet further provides use of a sulfated oligosaccharide to preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. | 2009-08-27 |
20090215718 | CARBOHYDRATE COMPOSITION FOR FLAT GLUCOSE RESPONSE - A low-glycemic available carbohydrate composition of the invention contains the following components:
| 2009-08-27 |
20090215719 | LOW MOLECULAR WEIGHT HYALURONIC ACID AND/OR SALT THEREOF, METHOD FOR PRODUCING SAME, AND COSMETIC PREPARATION AND FOOD COMPOSITION CONTAINING SAME - A low-molecular-weight hyaluronic acid and/or its salt is obtained by dispersing hyaluronic acid and/or its salt in an acidic water-containing medium. | 2009-08-27 |
20090215720 | Polysaccharides Compositions Comprising Fucans and Galactans and their Use to Reduce Extravasation and Inflammation - A use of an anti-inflammatory polysaccharides composition comprising fucans and galactans to inhibit the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of between about 2.5/1 (w/w) to about 40/1 (w/w), the galactans having a molecular weight higher than about 100 kDa, and the fucans having a molecular weight between about 0.1 kDa and 100 kDa. | 2009-08-27 |
20090215721 | DIETARY COMPOSITIONS AND RELATED METHODS OF USE - The present invention provides dietary compositions for mammalian consumption. In particular, the present invention provides compositions comprising pectin, a component comprising electrolytes, thickening agents, a sweetening agent, and water, and methods for making such compositions. In some embodiments, the dietary compositions are used for preventing and/or treating malabsorption dysfunction and associated disorders (e.g., short bowel syndrome, Crohn's disease). In some embodiments, the dietary compositions are used for preventing and/or treating colonic disorders (e.g., ulcerative colitis). The dietary compositions further find use in subjects with diarrhea, regardless of cause, subject suffering from gastric dumping syndrome, and obese patients or patients seeking to lose weight, as the composition delays gastric emptying (e.g., creating feeling of early satiety). In some embodiments, the dietary composition is a prebiotic food supplement. | 2009-08-27 |
20090215722 | Inhibition of Antigen Presentation with Poorly Catabolized Polymers - Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For example, these methods and compositions can be used to prevent the rejection of xenografted and allografted tissues in an animal. | 2009-08-27 |
20090215723 | Organic silicic acids complex for therapeutic and cosmetic applications - This invention describes materials containing organic silica, used in cosmetic for external uses (gel, cream or lotion) or for internal uses (microbeads/beads, tablets or solutions). These materials are vegetable extracts such as bamboo or algae which constitute richest sources in organic silica (more soluble and assimilable). After extraction in a basic medium, the organic silica extract can form a stable complex at acidic pH in presence of stabilizers such as gelatin, collagen, polyethylene glycol and/or chitosan, etc. These complexes can be used for cosmetic applications in gel, lotion and cream or as a matrix in order to immobilize various bioactive molecules. For internal uses, the soluble form of monomeric or oligomeric silicic acid is necessary to preserve its assimilability. In this context, the addition of stabilizers (gelatin and/or collagen) or the functionalization of silicic acid is possible to improve its solubility and biodisponibility. | 2009-08-27 |
20090215724 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2009-08-27 |
20090215725 | Substituted 4-aminocyclohexane derivatives - Substituted 4-aminocyclohexane derivatives having the formula I: | 2009-08-27 |
20090215726 | Phosphono-Pent-2-en-1-yl Nucleosides and Analogs - Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are 5-phosphono-pent-2-en-1-yl nucleosides and esters thereof. | 2009-08-27 |
20090215727 | INHIBITION OF ATP-MEDIATED, P2X7 DEPENDENT PATHWAYS BY PYRIDOXAL-5-PHOSPHATE AND VITAMIN B6 RELATED COMPOUNDS - P5P can be used as effective treatments for the modulation of P2X7, IL-1β, and inflammation response, and for diseases in which prevention of P2X7-dependent pathways or prevention of release of IL-1β is desirable, such as epithelial cancer, leukemia, brain tumors, spinal cord injury, tuberculosis, Alzheimer's Disease, neurodegenerative diseases, autosomal recessive polycystic kidney disease, diabetes, including type I diabetes, prostate cancer, and osteoporosis, bone formation and resorption. | 2009-08-27 |
20090215728 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use - This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: | 2009-08-27 |
20090215729 | MICROPARTICLE COMPOSITIONS TO MODIFY CANCER PROMOTING CELLS - This invention provides pharmaceutical compositions and methods related to the prevention and treatment of primary tumors and metastatic, malignant or spreading cancers by selectively targeting cancer associated myeloid derived cells by the targeted delivery of a bisphosphonate formulated with a non-liposomal particle carrier. In some aspects, the bisphosphonate particles have one or more properties suitable for phagocytosis by cancer associated myeloid derived cells and release of the bisphosphonate within the macrophages. Advantageously, administering the particles to a subject reduces the level and/or activity of cancer associated myeloid derived cells in the subject. | 2009-08-27 |
20090215730 | Antineoplastic compounds and pharmaceutical compositions thereof - Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes. | 2009-08-27 |
20090215731 | Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer - The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent. | 2009-08-27 |
20090215732 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA - The present invention provides pharmaceutical compositions comprising a glucocorticosteroid and a compound of formula: wherein m, R | 2009-08-27 |
20090215733 | THERAPY FOR THE PROPHYLAXIS OR TREATMENT OF ADVERSE BODY COMPOSITION CHANGES AND/OR DECREASED MUSCLE STRENGTH AFTER ANDROGEN OR GNRH ANALOGUE INTAKE - Methods of treating or reducing the risk of one or more effects or signs of induced hypogonadism after androgen or GnRH intake are disclosed herein. In an embodiment, a method of treating one or more effects after androgen or gonadotropin releasing hormone (GnRH) analogue intake comprises administering to a male subject at least one of a blocking compound which antagonizes estradiol binding to estradiol receptors or an inhibitor compound which inhibits endogenous production of estradiol, after androgen or gonadotropin releasing hormone (GnRH) analogue intake, to treat the one or more effects. The one or more effects include adverse body composition changes, decreased muscle strength, or both. The inhibitor compound and/or blocking compound may include antiestrogen agents, aromatase inhibitors, or combinations thereof. | 2009-08-27 |
20090215734 | METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS - Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided. | 2009-08-27 |
20090215735 | TOPICAL SOLUTION FORMULATIONS CONTAINING A CORTICOSTEROID AND A CYCLODEXTRIN - Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose. | 2009-08-27 |
20090215736 | CASPASE INHIBITORS AND USES THEREOF - This invention provides caspase inhibitors of formula I: | 2009-08-27 |
20090215737 | Pharmaceutical Compositions - 2 - The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations. | 2009-08-27 |
20090215738 | PREVENTION AND TREATMENT OF AN INCREASE IN CARDIOVASCULAR RISK, ADVERSE CARDIOVASCULAR EVENTS, INFERTILITY, AND ADVERSE PSYCHOLOGICAL EFFECTS AFTER ANDROGEN OR GNRH ANALOGUE INTAKE - Disclosed is a is a treatment for the adverse psychological effects (including depression, low self esteem, guilt, increased stress, anhedonia, decreased cognition, sleep disturbances, general fatigue, agitation/motor dyskinesia and decreased appetite) resulting from androgens or GnRH analogue intake, by administering a compound which antagonizes estradiol or its receptors, or blocks and prevents estradiol binding to the estradiol receptors (including antiestrogens) and/or a compound which inhibits endogenous production of estradiol, including aromatase inhibitors. Suitable antiestrogens include clomiphene and its isomer enclomiphene, tamoxifen, 4-hydroxytamoxifen, and toremifene. Suitable cytochrome P450 (P450arom) aromatase inhibitors include formestane, exemestane, anastrozole, and letrozole. | 2009-08-27 |
20090215739 | Chemical method of making a suspension, emulsion or dispersion of pyrithione particles - A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprising a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium. | 2009-08-27 |
20090215740 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS - A compound having a structure | 2009-08-27 |
20090215741 | 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use - The disclosure concerns compounds of general formula (I): | 2009-08-27 |
20090215742 | AMIDE RESORCINOL COMPOUNDS - The present invention is directed to compounds of formula (I), | 2009-08-27 |
20090215743 | Tricyclic benzazepine derivatives and their use - The present application relates to novel tricyclic benzazepine derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and ischaemias. | 2009-08-27 |
20090215744 | Solid Formulations - The present invention is directed to solid formulations of the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as preparations, and pharmaceutical uses thereof. | 2009-08-27 |
20090215745 | Association of a sinus node If current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it - Association comprising a selective and specific sinus node I | 2009-08-27 |
20090215746 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS CALCIUM RECEPTOR MODULATING AGENTS - There is provided a calcium receptor modulator comprising a compound of the formula (I): | 2009-08-27 |
20090215747 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES - This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed. | 2009-08-27 |
20090215748 | FXR agonists for treating vitamin D associated diseases - Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist. Also provided are certain methods of modulating levels of Cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) and 1α,25-dihydroxyvitamin D | 2009-08-27 |
20090215749 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR - The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. | 2009-08-27 |
20090215750 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2009-08-27 |
20090215751 | Use of Selective Chloride Channel Modulators to Treat Alcohol and/or Stimulant Substance Abuse - The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABA | 2009-08-27 |
20090215752 | Compounds, preparation and therapeutic use thereof - The invention relates to benzodiazepine derivatives having PDE2 inhibitory activities, as well as therapeutic methods of administering said compounds, in particular for treating various diseases of the central or peripheral nervous system. The invention further includes methods of preparing the subject compounds and pharmaceutical compositions containing them. | 2009-08-27 |
20090215753 | Topical Compositions for Paediatric Use - The present invention provides pharmaceutical compositions for treating a paediatric mammal, the compositions comprising a therapeutic agent and a pharmaceutically acceptable carrier, the composition being suitable for topical application resulting in transdermal administration of the therapeutic agent and a systemic therapeutic effect. The invention also provides relates uses of the compositions, applicators and kits. | 2009-08-27 |
20090215754 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS - The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na | 2009-08-27 |
20090215755 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICINAL PRODUCTS THAT ARE USEFUL IN THE PREVENTION AND TREATMENT OF DYSLIPIDAEMIAS AND OF DISEASES RELATED TO DYSLIPIDAEMIAS AND/OR TO OBESITY - Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB | 2009-08-27 |
20090215756 | FORMULATIONS CONTAINING LOSARTAN AND/OR ITS SALTS - The invention relates, in general, to new formulations and dosage units containing losartan and/or its salts (e.g., losartan potassium) that are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, and a process for making the same. The process generally includes (i) mixing and blending losartan potassium and a first portion of at least one of pre-gelatinized starch, microcrystalline cellulose and magnesium stearate to the mixture of step (i); (ii) compacting the mixture obtained in step (i) to form an agglomerate; (iii) breaking apart the agglomerate in order to obtain a granulate; (iv) adding lactose monohydrate and a second portion of at least one of pre-gelatinized starch, microcrystalline cellulose and magnesium stearate to the granulate and blending; and (v) tableting the granulate mixture into tablets. The process can further include coating the prepared tablets with a suitable coating material. | 2009-08-27 |
20090215757 | Process for Preparation of High-Purity Meloxicam and Meloxicam Potassium Salt - The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid to yield high-purity meloxicam. | 2009-08-27 |
20090215758 | Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs - The invention relates to 2,5-disubstituted thiazol-4-one derivatives and to their use in the production of drugs, to methods for producing them and to drugs containing said compounds. | 2009-08-27 |
20090215759 | MODULATORS FOR AMYLOID BETA - The invention relates to compounds of formula | 2009-08-27 |
20090215760 | SYNERGISTIC INSECTICIDE MIXTURES - The invention relates to insecticidal mixtures, comprising ethiprole and at least one other known active substance, belonging to the neonicotinoid family as well as to the use of said mixtures for controlling animal pests. | 2009-08-27 |
20090215761 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF - The present invention relates to quinobenzoxazines analogs having the general formula: | 2009-08-27 |
20090215762 | Siloxane polymer containing tethered levofloxacin - A polymer that is a polysiloxane polymer has Levofloxacin groups, or pharmaceutically acceptable salts thereof, attached via linkers. The linkers may be hydrolytically labile thereby providing a manner of releasing the Levofloxacin from the polymer. | 2009-08-27 |
20090215763 | SUBSTITUTED BENZOXAZINONES - The present invention provides substituted oxazinone compounds, such as substituted benzoxazinones, which exhibit potent renin inhibition activities. | 2009-08-27 |
20090215764 | Antimicrobial agents - Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds described herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal organisms, more particularly against bacterium, for example, | 2009-08-27 |
20090215765 | Neuroprotective compounds for treating optic neuropathies - Neuroprotective compounds for treating optic neuropathies and screening methods for identifying neuroprotective compounds. | 2009-08-27 |
20090215766 | TETRACYCLIC INHIBITORS OF JANUS KINASES - The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer. | 2009-08-27 |
20090215767 | ISOFLAVONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - An isoflavone derivative is provided. The isoxazole derivative has following formula: | 2009-08-27 |
20090215768 | ISOXAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - An isoxazole derivative is provided. The isoxazole derivative has following formula: | 2009-08-27 |
20090215769 | Use of soluble guanylate cyclase activators for the treatment of Raynaud's Phenomenon - The present invention relates to a method for prevention or treatment of primary and secondary Raynaud's phenomenon comprising administration of an effective amount of a compound selected from compounds of formulae I-IV, and to pharmaceutical compositions containing these compounds. | 2009-08-27 |
20090215770 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases - The invention provides quinazoline derivatives of formula (I): | 2009-08-27 |
20090215771 | JNK INHIBITORS - The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. | 2009-08-27 |
20090215772 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 - The invention provides compounds of the formula (I): | 2009-08-27 |
20090215773 | DIHYDROPYRIDINE DERIVATIVES - The present invention relates to dihydropyridine derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2009-08-27 |
20090215774 | USES OF INDANE COMPOUNDS - The invention provides methods of treating obesity and eating disorders, which comprise administering indane compounds of Formula (I): | 2009-08-27 |
20090215775 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer - Compounds of formula (I) are disclosed for treatment of cancer. | 2009-08-27 |
20090215776 | Organic compounds - Compounds of formula I | 2009-08-27 |
20090215777 | Pyrimidine Derivatives As HSP90 Inhibitors - The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR | 2009-08-27 |
20090215778 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives - Derivatives of pyrazolopyrimidine compounds represented by Formula I are disclosed: | 2009-08-27 |
20090215779 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS - Compounds of Formula (I): | 2009-08-27 |
20090215780 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 2009-08-27 |
20090215781 | ALPHA-HELIX MIMETICS AND METHODS RELATING TO THE TREATMENT OF FIBROSIS - The invention provides α-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R | 2009-08-27 |
20090215782 | Use of PDE-5 Inhibitors for Endothelial Repair of Tissues Impaired by Trauma or Disease - The invention relates generally to neovascularization and endothelial repair of tissues impaired by trauma or disease. Particularly, the invention relates to the function of endothelial progenitor cells in neovascularization and endothelial repair. More particularly, the invention relates to methods and pharmaceutical compositions for the treatment of tissues impaired by trauma or disease. In particular, the present invention relates to the use of a type V phosphodiesterase inhibitor in the preparation of a medicament for the treatment of a condition which is susceptible to the treatment with circulating EPCs wherein the treatment is effected by the proliferation of endothelial progenitor cells. | 2009-08-27 |
20090215783 | COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL DIFFERENTIATION - The present invention relates to composition and methods for inducing or inhibiting differentiation of stem cells. The invention also relates to applications in the treatment of medical conditions, e.g., osteoporosis, bone fracture, bone injuries, myocardiac infarction, cardiomyopathy, degenerative muscle diseases, myopathy, and urinary incontinence. | 2009-08-27 |
20090215784 | Maleate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-oxo-6,7-- dihydro-5H-Pyrrolo[3,4-b]Pyrazine - A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided. | 2009-08-27 |
20090215785 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2009-08-27 |
20090215786 | NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS - The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use. | 2009-08-27 |
20090215787 | Preparations of new polymorphic forms of varenicline tartrate - The present invention is directed to an amorphous form, three novel polymorph form of crystalline varenicline tartrate, namely Form D, Form E and Form F. The present invention also provides processes of their preparations and pharmaceutical composition comprising such material and their use in therapy. Form D is new anhydrous varenicline tartrate, and can be prepared from recrystallizing varenicline tartrate in a mixture of methanol and water or a mixture of N,N-dimethylformamide and water. Form E is a new varenicline tartrate monohydrate, and can be prepared recrystallizing varenicline tartrate in a mixture of isopropanol and water. Form F is another new varenicline tartrate monohydrate, and can be prepared recrystallizing varenicline tartrate in a mixture of acetone and water. The X-ray powder diffraction pattern (X-RPD), Fourier transform infrared (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) techniques are used to characterize amorphous form and crystalline polymorphic forms. | 2009-08-27 |
20090215788 | Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 2009-08-27 |
20090215789 | CYCLIC HEXADEPSIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS - The present invention provides cyclic hexadepsipeptides and their pharmaceutically acceptable salts, solvates and prodrugs, and methods for obtaining the compounds, by fermentation, optionally followed by post-biosynthesis chemical modification. The present invention further provides uses of cyclic hexadepsipeptides, and their pharmaceutically acceptable salts, solvates and prodrugs as pharmaceuticals, in particular to their use as antibacterial, antifungal or antineoplastic agents, and to pharmaceutical compositions comprising a cyclic hexadepsipeptide, or a pharmaceutically acceptable salt, solvate or prodrug thereof, together with a carrier. | 2009-08-27 |
20090215790 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof - The invention relates to novel oxindole derivatives of general formula (I), in which the substituents R | 2009-08-27 |
20090215791 | NEW THERAPEUTIC USE OF 4-(2-FLUOROPHENYL)-6-METHYL-2-(1-PIPERAZINYL)THIENO[2,3-D]PYRIMIDINE - 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain. | 2009-08-27 |
20090215792 | METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA CELLS - Here, the inventors disclose the treatment of imatinib mesylate resistant chronic myelogenous leukemia cells with a cotreatment of vorinostat (SAHA, suberoylanilide hydroxamic acid) and dasatinib, a dual Abl/Src kinase (TK) inhibitor. Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent alone, as well as synergistically induced loss of clonogenic survival, which was associated with greater depletion of Bcr-Abl, p-CrkL and p-STAT5 levels. Co-treatment with dasatinib and vorinostat also attenuated the levels of Bcr-AblE255K and Bcr-AblT315I and induced apoptosis of BaF3 cells with ectopic expression of the mutant forms of Bcr-Abl. Finally, co-treatment of the primary CML cells with vorinostat and dasatinib induced more loss of cell viability and depleted Bcr-Abl or Bcr-AblT315I, p-STAT5 and p-CrkL levels than either agent alone. | 2009-08-27 |
20090215793 | Methods for treating drug resistant cancer - A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, wherein the patient is a cancer patient with drug-resistant cancer, wherein the compound of Formula I is as defined in the application. | 2009-08-27 |
20090215794 | SEROTONERGIC AGENTS - Novel piperazine derivatives are provided having the formula | 2009-08-27 |
20090215795 | CYCLIC AMIDINE DERIVATIVES - A cyclic amidine derivative represented by the formula: | 2009-08-27 |
20090215796 | Compositions, Kits and Methods for a Titration Schedule for Pardoprunox Compounds - The present invention is directed to compositions, kits, and methods for a titration schedule to facilitate the treatment of a central nervous system condition or disorder by administering a plurality of dosage units of a composition comprising a compound 7-(4-methyl)-1-piperazinyl-2(3H)-benzoxazolone (INN pardoprunox). | 2009-08-27 |
20090215797 | STABLE EMULSIFIABLE CONCENTRATE FORMULATION - The use of an N,N-dimethyl alkylamide or an N-alkanoyl morpholine provides a stable emulsifiable concentrate composition that hinders de-esterification and transesterification of mixtures of a carboxylic acid herbicide and an ester of a different carboxylic acid herbicide. The N,N-dimethyl alkylamide or N-alkanoyl morpholine additionally stabilizes emulsifiable concentrates containing a triazolopyrimidine herbicide having at least one methoxy group on the triazolopyrimidine ring. | 2009-08-27 |
20090215798 | Inhibitor Compounds - The present invention relates to compounds and uses of compounds which interact with chitinase enzymes, in particular inhibition of those enzymes. | 2009-08-27 |
20090215799 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES - The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 2009-08-27 |